[Treatment of acute myocardial infarction in Peru and its relationship with in-hospital adverse events: results from the second peruvian registry of ST-segment elevation myocardial infarction (PERSTEMI-II).]
Manuel Chacón DiazRené Rodríguez OlivaresDavid Miranda NoéPiero Custodio-SanchezAlexander Montesinos CárdenasGermán Yábar GalindoAida Rotta RottaRoger Isla BazánPaol Rojas de la CubaNassip Llerena NavarroMarcos López RojasMauricio García CárdenasAkram Hernández-VásquezPublished in: Archivos peruanos de cardiologia y cirugia cardiovascular (2021)
Fibrinolysis continues to be the most frequent reperfusion therapy in public hospitals in Peru. Shorter ischemia-to-reperfusion time was associated with reperfusion success, and in turn with fewer in-hospital adverse events.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- healthcare
- acute coronary syndrome
- cerebral ischemia
- coronary artery disease
- adverse drug
- left ventricular
- acute care
- acute ischemic stroke
- atrial fibrillation
- mental health
- emergency department
- heart failure
- subarachnoid hemorrhage
- blood brain barrier
- sensitive detection
- cell therapy
- mesenchymal stem cells
- replacement therapy